Document 3014
 DOCN  M94A3014
 TI    Effect of interferon alpha 2A on serum androgen in HIV+ men with
       Kaposi's sarcoma.
 DT    9412
 AU    Christeff N; Gharakhanian S; Thobie N; Wirbel E; Rozenbaum W; Nunez EA;
       U224 INSERM, CHU Bichat, Paris.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):173 (abstract no. PB0120). Unique
       Identifier : AIDSLINE ICA10/94369561
 AB    OBJECTIVE: To compare the serum androgen concentrations of HIV+ men with
       Kaposi's sarcoma (KS), before, during and after treatment with
       recombinant alpha-2a interferon (INF) (Hoffman-La Roche). We have
       detected high serum androgen levels in HIV+ KS men. METHODS: Serum from
       22 HIV+ men with KS were analysed for androgens: dehydroepiandrosterone
       (DHEA), DHEA sulfate (DHEAs), androstenedione (delta 4), testosterone
       (T) by RIA before (1), during (2) and after (3) treatment with INF. The
       results were compared 2 versus 1, 3 versus 1 and 2 versus 3 and
       interpreted in terms of the clinical remission of KS. RESULTS: All the
       patients, except one, were homosexual. TABULAR DATA, SEE ABSTRACT
       VOLUME. All androgens concentrations dropped during INF treatment, and
       remained low after treatment. The decrease of androgen are for DHEA
       -50%, p < 0.01; DHEAs -35%, p < 0.01; delta 4 -40%, p < 0.01 and T -40%,
       p < 0.01. 18 of the 22 men treated achieved complete remission of their
       HIV-related KS. CONCLUSION: Treatment of HIV+ men suffering from KS with
       IFN lowered their serum androgen levels particularly that of DHEA. This
       decrease coincided with the complete clinical remission of these
       patients. But there was no correlation with the changes in CD4 count.
       These data suggest that androgens may be involved in the appearance of
       KS and could provide a new therapeutic approach to this syndrome.
 DE    Androgens/*BLOOD  Follow-Up Studies  Human  HIV
       Seropositivity/BLOOD/*THERAPY  Interferon Alfa-2a/*THERAPEUTIC USE  Male
       Sarcoma, Kaposi's/BLOOD/*THERAPY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).